Skip to Main Content

We have a new app!

Take the Access library with you wherever you go—easy access to books, videos, images, podcasts, personalized features, and more.

Download the Access App here: iOS and Android. Learn more here!

For further information, see CMDT Part 21-14: Hypermagnesemia

Key Features

  • Serum magnesium > 3.0 mg/dL (> 1.25 mmol/L)

  • Almost always the result of advanced stages of chronic kidney disease (CKD) and impaired magnesium excretion

  • Pregnant patients may have severe hypermagnesemia from intravenous magnesium therapy for preeclampsia and eclampsia

  • Magnesium replacement should be done cautiously in patients with CKD, and dose reductions up to 75% may be necessary to avoid hypermagnesemia

Clinical Findings

  • Muscle weakness

  • Decreased deep tendon reflexes

  • Mental obtundation

  • Confusion

  • Weakness, even flaccid paralysis

  • Ileus, hypotension

  • In severe cases, respiratory muscle paralysis, complete heart block, or cardiac arrest


  • Serum magnesium > 3.0 mg/dL (> 1.25 mmol/L)

  • In the common setting of CKD, elevated blood urea nitrogen, serum creatinine, phosphate, and uric acid; serum K+ may be elevated

  • Serum Ca2+ is often low

  • ECG may show increased PR interval, broadened QRS complexes, and QT prolongation


  • Exogenous sources of magnesium should be discontinued

  • Calcium antagonizes Mg2+ and may be given intravenously as calcium chloride, 500 mg or more at a rate of 100 mg (4.1 mmol)/min

  • Hemodialysis may be indicated

  • Long-term use of magnesium hydroxide and magnesium sulfate should be avoided in patients with advanced stages of CKD

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.